Business
PNB shares jump 4% after Q4 results but Jefferies, Motilal, other brokerages are cutting target prices; here’s why
The PSU bank released its results on Tuesday. Its net interest income (NII) declined nearly 4% to Rs 10,380 crore in the January-March quarter of the financial year 2026, from Rs 10,757 crore in the corresponding quarter of the previous financial year.
Asset quality improved sequentially, with gross NPA ratio reducing to 2.95% in Q4 FY26 from 3.19% in Q3 FY26. Meanwhile, the Net NPA ratio reduced to 0.29% in the quarter under review, from 0.32% in the previous quarter.
Along with the Q4 results, PNB announced a dividend of Rs 3 per equity share, equivalent to 150% of the face value of Rs 2 each.
Jefferies on PNB
Jefferies maintained its ‘Buy’ rating for the shares of PNB, but reduced its target price to Rs 130 apiece from Rs 134 apiece. The latest target price implies an upside potential of more than 20% from the stock’s previous closing price of Rs 107.89 apiece on NSE.
The international brokerage said that the company’s profit beat expectation, as reversal of retirement benefits and write-back of provisions compensated for weaker NII. It highlighted that the bank’s loan growth was led by overseas and MSME segment. Corporate growth was broadly inline while retail was softer.
Jefferies said that the NII disappointed for another quarter with NIM contracting 5bps QoQ and 34bps YoY due to the impact of the repo rate cut and limited easing in deposit costs. Deposit growth remained stable at 9% YoY and with an LDR ratio of 72%, bank can continue to grow loans faster than deposits, the brokerage said. “Even as management expects a gradual NIM recovery, supported by a higher share of RAM loans, improved CASA mix, and lower incremental deposit costs, we see risks to guidance due to lower exit rate of margins,” it added.
It highlighted that bank benefited from the release of standard asset provisions of Rs 7 billion, following changes in the RBI’s large borrower framework. “We tweak earnings as we factor in lower margins, offset by lower opex & provisions. We expect the bank to deliver 12% Cagr in loans over FY26-29, credit costs of 0.4% and see the bank delivering ROA of 0.8% in FY27,” Jefferies said.
Motilal Oswal on PNB
Motilal Oswal Financial Services maintained its ‘Buy’ rating for PNB shares but reduced its target price to Rs 135 apiece. The latest target price implies an upside potential of more than 25% from the stock’s previous closing price.
“PNB reported a mixed quarter, with earnings beat led by controlled provisions and opex, while margins declined by 5bp QoQ. Provisions came in lower, aided by a reversal of standard provisions, while opex was lower due to a reversal in AS-15-related expenses. Business growth remained modest, and management guided for loan growth of ~12-13% in FY27. Asset quality trends were healthy, although slippages saw a marginal uptick on account of seasonality,” it said.
Elara Capital on PNB
Elara Capital held an ‘Accumulate’ call on the shares of PNB and cut its target price to Rs 125 apiece, implying an upside potential of around 16% from the stock’s previous closing price. PNB delivered softer Q4 FY26, and the overall trends have been volatile, the brokerage said.
“The investment argument thus relies on recovery potential than on core delivery, which we still believe has some catch -up to do. Following higher-than- expected NIM pressure, we prune our EPS by 2-3% for FY27E,” it added.
Emkay on PNB
Emkay retained its ‘Buy’ call on PNB shares but reduced its target price to Rs 135 apiece. “Considering moderate growth, margins, and pressure on treasury, we trim our earnings estimate by 5-7% and cut our target price to Rs 135 (based on 0.9x FY28E ABV + subs/investment value at Rs 10/share),” the brokerage said.
It cited the stock’s cheap valuations for the ‘Buy’ call.
PNB share price
PNB shares jumped nearly 4% to trade at Rs 111.74 apiece on NSE on Wednesday morning. After the release of the results on Tuesday, the stock closed nearly 1% lower. The shares of the company have fallen around 1% in one week but gained 3% in one month. The stock jumped 16% in one year.
From the lens of a longer term, the shares of Punjab National Bank have surged 109% in three years and more than 200% in five years.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Business
Miura Co., Ltd. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Business
Mitsui Chemicals, Inc. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:MITUY) 2026-06-06
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Business
I Have Been Patiently Waiting For This Market Meltdown
JR Research is an opportunistic investor. I was recognized by TipRanks as a Top Analyst, and also by Seeking Alpha as a “Top Analyst To Follow” for Technology, Software, and Internet, as well as for Growth and GARP. I identify attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. My picks have consistently demonstrated market outperformance over time. My approach combines timely and sharp price action analysis with fundamentals as my foundation. I also tend to avoid overhyped and overvalued stocks while capitalizing on battered stocks with significant upside recovery possibilities. I run the investing group Ultimate Growth Investing which specializes in identifying high-potential opportunities across various sectors. My main ideas revolve around stocks with strong growth potential, and also well-beaten contrarian plays. I designed the group for investors seeking to capitalize on growth stocks with solid fundamentals, robust buying momentum, and appealing turnaround plays to generate alpha consistently. Learn more
Analyst’s Disclosure: I/we have a beneficial long position in the shares of PLTR, CRM, NOW, MSFT, QQQ, SPY, META , GOOGL, NVDA, PANW, CRWD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Business
SRS Holdings Co.,Ltd. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:SRSYF) 2026-06-06
Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team
Business
Healthcare Stocks Can Benefit From AI, Too. But That Isn’t the Reason to Buy Them.
Healthcare Stocks Can Benefit From AI, Too. But That Isn’t the Reason to Buy Them.
Business
What Will SpaceX’s IPO Mean for Your Index Funds?
What Will SpaceX’s IPO Mean for Your Index Funds?
Business
Target recalls popular baby wipes after FDA finds potentially harmful bacteria
Check out what’s clicking on FoxBusiness.com.
Target is recalling several Up & Up baby wipes products sold nationwide after testing identified potentially dangerous bacteria that could cause serious infections, particularly in infants and young children.
According to a recall notice posted Friday by the U.S. Food and Drug Administration (FDA), Target is voluntarily recalling certain lots of Up & Up Fragrance Free Baby Wipes and Up & Up Fresh Cucumber Scented Baby Wipes following customer complaints about product discoloration.
FDA testing identified the presence of Burkholderia cepacia complex and Burkholderia gladioli in samples of the affected wipes.
Health officials warned that products contaminated with the bacteria could lead to serious and potentially life-threatening infections. The wipes are primarily used on newborns, infants and young children, a group considered particularly vulnerable because of their developing immune systems.
TARGET TO CUT PRICES ON 3,000 ITEMS AS INFLATION REMAINS ABOVE FED TARGET

Up & Up Fragrance Free Baby Wipes sold at Target stores nationwide are included in a voluntary recall announced June 2026. (FDA / Unknown)
The FDA said healthy individuals who use the contaminated wipes on skin with minor cuts or abrasions may develop localized infections. However, infections in immunocompromised individuals, newborns and infants could spread into the bloodstream and potentially cause sepsis or pneumonia.
The recalled wipes were manufactured by supplier Sapro Temizlik Urunleri and sold at Target stores nationwide as well as through Target.com.
Target and the manufacturer have received a number of consumer complaints and adverse event reports alleging product discoloration and symptoms including skin irritation, eye irritation and infections that may be linked to use of the wipes. The reports remain under investigation.
A representative for Target did not immediately respond to FOX Business’ request for comment.
TARGET SET TO OPEN ITS 2,000TH STORE, PLANS TO OPEN HUNDREDS MORE IN NEXT DECADE

A three-pack of Up & Up Fresh Cucumber Scented Baby Wipes is shown. Target is recalling certain baby wipes products after FDA testing identified potentially harmful bacteria in product samples. (FDA / Unknown)
The recall affects multiple sizes of Up & Up Fragrance Free Baby Wipes, including 20-count, 72-count, 216-count, 800-count and 1,200-count packages, as well as Up & Up Fresh Cucumber Scented Baby Wipes sold in 72-count, 216-count and 800-count packages.
Consumers are being urged to stop using the recalled wipes immediately and return them to any Target store for a full refund.
Target said customers seeking additional information can contact Target Guest Relations at 1-800-440-0680.
The recall is being conducted with the knowledge of the U.S. Food and Drug Administration, and Target said it is continuing to investigate the matter in coordination with the manufacturer.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| TGT | TARGET CORP. | 122.57 | -1.28 | -1.03% |
According to the FDA, the affected Up & Up Fragrance Free Baby Wipes were manufactured between Nov. 7, 2025, and May 5, 2026, and carry expiration dates ranging from May 10, 2028, through Nov. 5, 2028.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The recalled Up & Up Fresh Cucumber Scented Baby Wipes were manufactured between Dec. 29 and Dec. 30, 2025, and carry expiration dates ranging from June 29, 2028, through June 30, 2028.
A complete list of affected UPCs, manufacturing codes and package sizes is available in the FDA recall notice.
Business
Senseonics Holdings, Inc. (SENS) Shareholder/Analyst Call Transcript
Tim Goodnow
President, CEO & Director
Thanks for joining us. And as we update you folks on the Senseonics story, it’s a pretty exciting time for us. As many of you know, for those that were able to join us a year ago, we had a partnership with the PHC Corporation for the commercial activities. We’ve transitioned that since we last spoke. And it’s a pretty exciting time for us as we’ve been able to leverage that experience and that capability significantly with our strategic investment into the commercial organization. And frankly, we’re very excited with the commercial results that we’re now getting.
So obviously, the control of our destiny is very, very important, because it gives us the ability to pivot and move quick, make adjustments, expand those areas that make the most sense and frankly, leverage the internal capability. But we’ve been able to do that because, although we did the transition, we’ve essentially brought the entire Ascensia commercial organization over under Brian’s leadership, and that really has made a seamless process that we’ve been very excited to be able to execute against.
We also made the decision as part of that transition in the last year that the primary issue for growth with Eversense in a highly competitive market, but a very attractive market really had to
Business
STK: Still Has Room To Run But Isn’t As Attractive (NYSE:STK)
Financial analyst by day and a seasoned investor by passion, I’ve been involved in the world of investing for over 15 years and honed my skills in analyzing lucrative opportunities within the market.I specialize in uncovering high quality dividend stocks and other assets that offer potential for long term-growth that pack a serious punch for bill-paying potential. I use myself as an example that with a solid base of classic dividend growth stocks, sprinkling in some Business Development Companies, REITs, and Closed End Funds can be a highly efficient way to boost your investment income while still capturing a total return that follows traditional index funds. I created a hybrid system between growth and income and manage to still capture a total return that is on par with the S&P.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of STK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Business
My Bullish Call On Bank Of America Aligns With Its Seeking Alpha Quant Rating (NYSE:BAC)
As an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading strategies, proper execution of my trading plan, and absolute investing results are my goals. I see my articles as a way to keep me focused on developing winning trades. I also expect to learn much from the feedback that is provided in the comments section.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in BAC over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
-
Business5 days agoJade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Development Plans Transcript
-
Fashion1 day agoWeekend Open Thread: Evereve – Corporette.com
-
Sports4 days agoFrench Open 2026 results: Alexander Zverev beats Rafael Jodar and will play Jakub Mensik in semi-finals
-
Crypto World1 day ago
Jensen Huang Approves Samsung, SK Hynix, and Micron for NVIDIA (NVDA) HBM4 Memory Supply
-
Tech4 days agoCryZENx Releases Fresh Playable Content Deep Inside Jabu-Jabu for His Ocarina of Time Remake
-
Business4 days agoTrump Taps Housing Chief Bill Pulte as Acting Intelligence Director After Gabbard Exit
-
Crypto World2 days ago
LBank Surpasses 25 Million Users Worldwide as AFA Partnership Continues to Drive Global Growth
-
NewsBeat4 days agoRepublicans balk at Trump’s attempt to appoint a MAGA enforcer to lead National Intelligence
-
Crypto World4 days ago
Seagate (STX) Stock Surges to Record High on AI Boom and Legal Settlement
-
Tech1 day agoRCS Messages Between iPhone and Android Get End-to-End Encryption With iOS 26.5
-
Crypto World4 days agoEU AI Data Center Project Faces Delays as Funding Gaps Grow
-
Entertainment4 days agoDid The Mandalorian And Grogu Already Ruin The Next Star Wars Movie?
-
Business4 days agoAehr Test Systems Stock Soars 17% Amid Surging AI Demand and Conference Spotlight
-
Business4 days agoClaude AI Down Today Reason: Why Anthropic’s AI is not working today? What’s the latest quota update
-
Business4 days agoRelay Therapeutics Shares Surge 20% on ASCO Momentum for Zovegalisib Breast Cancer Program
-
Tech4 days agoInstagram will stop bombarding teens with the same kind of obsessively unhealthy content
-
Crypto World1 day ago
Merlin (MRLN) Stock Soars 32% on Major USSOCOM Autonomy Milestone
-
Tech1 day agoCredit card theft campaign abuses Stripe to host stolen payment info
-
Crypto World5 days agoTether Brings Google’s TurboQuant to Production, Unlocking Long-Context AI on Everyday Devices
-
Entertainment4 days ago‘Aliens’ Star Reveals How the US Military Co-Opted James Cameron’s Sci-Fi Tech [Exclusive]

You must be logged in to post a comment Login